Prevention of CNS relapse in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Hematology
• Clinical Research

Background:

• Central nervous system (CNS) relapse occurs in approximately 5% of diffuse large B-cell lymphoma (DLBCL) patients, often leading to a poor prognosis.
• Existing risk factors for CNS recurrence in DLBCL lack sufficient sensitivity and specificity for accurate prediction.
• The introduction of rituximab has altered the landscape of DLBCL treatment and CNS relapse patterns.

Purpose of the Study:

• To review CNS events in DLBCL studies before and after rituximab introduction.
• To evaluate the evidence supporting current CNS prophylactic strategies.
• To provide recommendations for managing CNS relapse risk in DLBCL patients.

Main Methods:

• Systematic review of published reports on CNS events in major DLBCL studies.
• Analysis of treatment strategies, including intrathecal chemotherapy and high-dose intravenous chemotherapy.
• Assessment of risk factors and patient subgroups associated with CNS relapse.

Main Results:

• Current CNS prophylaxis strategies, including intrathecal chemotherapy, are based on limited evidence and should not be routinely administered, particularly after rituximab introduction.
• Specific patient subgroups, such as those with testicular lymphoma or multiple extranodal sites with additional risk factors, may have a higher risk of systemic and CNS relapse.
• Prophylactic intrathecal chemotherapy is not recommended due to rare isolated leptomeningeal relapses, lack of proven efficacy, and potential side effects.

Conclusions:

• Routine CNS prophylaxis in DLBCL is not supported by current evidence, especially in the era of rituximab.
• High-risk patient subgroups require careful consideration for management strategies.
• High-dose intravenous methotrexate is a potential alternative for CNS relapse prevention that warrants further validation in prospective trials.